Clinical trial · Observational
Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care
Assessment of 4 Bone Turnover Markers (C-terminal Telopeptides of Type I Collagene (CTX), Amino-terminal Telopeptide of Type 1 Collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in Multiple Myeloma Patients Treated With Intravenous Bisphosphonate
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Inability to conduct the study
Summary
Brief summary (as posted)
The aim of this study is looking at the Kinetics of bone turnover markers (C-terminal telopeptides of type I collagene (CTX), amino-terminal telopeptide of type 1 collagen (NTX), Dickkopf-1 (DKK-1) and Sclerostin (SOST)) in serum and urine until 12 months in Patients with Multiple Myeloma Treated With intravenous bisphosphonates in routine care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood and urine collection | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- intravenous biphosphonate
- description
- Patients treated with intravenous bisphosphonate until 12 months in routine care
- interventionNames
- Biological: Blood and urine collection
Primary outcomes (1)
- measure
- Changes in bone turnover markers
- timeFrame
- Baseline, then every 2 months in 12 months
- description
- bone turnover markers include: C-terminal telopeptides of type I collagene (CTX) in serum, amino-terminal telopeptide of type 1 collagen (NTX) in urine, Dickkopf-1 (DKK-1) and Sclerostin (SOST) in plasma
Secondary outcomes (7)
- measure
- time to maximum variation of bone turnover markers
- timeFrame
- Baseline, then every 2 months in 12 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient aged 65 to 75 years of age 2. Patient with symptomatic multiple myeloma as defined by the criteria of the IMWG 3. Need to introduced an antiresorptive bone treatment by intravenous bisphosphonate with bone imaging mapping (PET-scanner preferentially) in routine care 4. Ability and willingness to follow scheduled visits with requested biological samples Exclusion Criteria \- Patients previously treated with intravenous biphosphonate
References
Publications (0)
Data not yet available